Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E, Toutirais O, Tougeron D, Drouet A, Le Gallo M, Desille M, Cabillic F, de La Pintière CT, Iero M, Rivoltini L, Baert-Desurmont S, Leprince J, Vaudry H, Sesboué R, Frébourg T, Latouche JB, Catros V. Fauquembergue E, et al. Among authors: de la pintiere ct. J Immunother. 2010 May;33(4):402-13. doi: 10.1097/CJI.0b013e3181d366da. J Immunother. 2010. PMID: 20386466
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F. Cabillic F, et al. Among authors: de la pintiere ct. Cancer Immunol Immunother. 2010 Nov;59(11):1611-9. doi: 10.1007/s00262-010-0887-0. Epub 2010 Jun 26. Cancer Immunol Immunother. 2010. PMID: 20582413 Free PMC article.
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.
Lavoué V, Cabillic F, Toutirais O, Thedrez A, Dessarthe B, de La Pintière CT, Daniel P, Foucher F, Bauville E, Henno S, Burtin F, Bansard JY, Levêque J, Catros V, Bouet-Toussaint F. Lavoué V, et al. Among authors: de la pintiere ct. Int J Cancer. 2012 Aug 15;131(4):E449-62. doi: 10.1002/ijc.27353. Epub 2011 Dec 21. Int J Cancer. 2012. PMID: 22095289
Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
Cabillic F, Bouet-Toussaint F, Toutirais O, Rioux-Leclercq N, Fergelot P, de la Pintière CT, Genetet N, Patard JJ, Catros-Quemener V. Cabillic F, et al. Among authors: de la pintiere ct. Clin Exp Immunol. 2006 Dec;146(3):518-23. doi: 10.1111/j.1365-2249.2006.03212.x. Clin Exp Immunol. 2006. PMID: 17100773 Free PMC article.
Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.
Bouet-Toussaint F, Patard JJ, Gervais A, Genetet N, de la Pintière CT, Rioux-Leclercq N, Toutirais O, Thirouard AS, Ramée MP, Catros-Quemener V. Bouet-Toussaint F, et al. Among authors: de la pintiere ct. Cancer Immunol Immunother. 2003 Nov;52(11):699-707. doi: 10.1007/s00262-003-0412-9. Epub 2003 Jul 15. Cancer Immunol Immunother. 2003. PMID: 12879292 Free PMC article. Clinical Trial.